Duplicate Prescriptions – FortisRx’s computer system checks against the recipients file for an identical prescription issued by that pharmacy or another pharmacy. If the same prescription is found, the pharmacist is alerted on-line with an appropriate message and the physician is notified.
Therapeutic Duplication – FortisRx’s computer system alerts the pharmacist to duplicate drug therapies (e.g., Inderal and Toprol). Pharmacists clarify these orders with prescribers to preclude filling therapeutically duplicate prescriptions.
Too Early Refill – A parameter is set as a function of the percentage of the original prescription days supply. For example, if this is set at 75 percent of a 32 days supply, the claimant may obtain a refill after the 24th day, but not before.
Drug Interactions – FortisRx’s computer system scans for severe drug interactions. A pharmacist evaluates the nature of the interaction and decides upon an appropriate course of action. In a case with potentially dangerous interaction, the pharmacist routinely confers with the prescriber. In less critical cases, the pharmacist may confer with the prescriber or the patient.
Drug Allergies – FortisRx’s patient profile database includes listings of drug allergies. The computer system scans new orders against the allergy database and alerts the pharmacist to the potential for an allergic reaction. When an allergy is detected, the pharmacist contacts the prescriber to recommend a different medication.
Drug-to-Medical Condition Conflict – The Medi-Span Drug-Disease Monitoring System, licensed by FortisRx, consists of a series of files that relate diseases treated by drug products, products contraindicated in certain disease states, messages to specify the disease state, a description of the disease state, and the disease states for which each drug is most commonly prescribed. Using this system and previous prescription history, the pharmacist is alerted when the potential for a drug-disease conflict is indicated. The pharmacist can then contact the prescribing physician for appropriate action.
Compliance Check – On a refilled prescription, a comparison is made of the expected number of days since the last fill and the actual number of days elapsed. If the actual number of days exceeds the expected number by more than 14 days (on a 90 day prescription), a message is sent to the pharmacist that the patient may be non-compliant.
Duration of Therapy – Many drugs have an FDA established guideline for minimum or maximum length of therapy needed for a positive therapeutic effect. If the prescribed drug has a maximum or minimum length of therapy identified in its drug records, and the days of therapy fall below or above the set parameters, a message is sent to the pharmacist that consultation with the physician may be appropriate.
High Dose – if a prescription has been written for more than 200 percent of the maximum recommended FDA adult dose or the pharmacist enters an inaccurate days supply which would result in a dosage more than double the FDA adult dose recommendations, the physician will be contacted.
Therapeutic Substitution – the pharmacist will consult with the physician to offer a generic medication over a brand name medication not only to lower cost, but the generic may be the drug of choice for their particular disease state.